Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Alzheimer’s Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 11(3), 332–384 (2015).
  MedlineGoogle Scholar
• 2 Schneider LS, Mangialasche F, Andreasen N et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to J. Intern. Med. 275(3), 251–283 (2014). • This review article discussed the last three decades of late-stage drug development for Alzheimer’s disease (AD) treatment.
  CASGoogle Scholar
• 3 Frisardi V, Solfrizzi V, Imbimbo BP et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer Res. 7(1), 40–55 (2010).
  Medline CASGoogle Scholar
• 4 Panza F, Solfrizzi V, Imbimbo BP, Logroscino G. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? Expert Opin. Biol. Ther. 14(10), 1465–1476 (2014).
  Medline CASGoogle Scholar
• 5 Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem. Pharmacol. 88(4), 529–539 (2014). • This was a comprehensive review article describing the background of repeated failures of treatment approaches based on the β-amyloid cascade theory of AD, proposing the basis for the development of tau aggregation inhibitors (TAIs) for AD treatment.
  Medline CASGoogle Scholar
• 6 Martin L, Latypova X, Wilson CM et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12(1), 289–309 (2013).
  Medline CASGoogle Scholar
• 7 Iqbal K, Gong CX, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert Opin. Ther. Targets 18(3), 307–318 (2014).
  Medline CASGoogle Scholar
• 8 Panza F, Frisardi V, Solfrizzi V et al. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4(2), 213–238 (2012).
  CASGoogle Scholar
• 9 Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol. Med. 21(6), 394–402 (2015). • A comprehensive and very updated review of the principal tau-based active and passive immunization approaches.
  Medline CASGoogle Scholar
• 10 Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33(1), 95–130 (2000).
  Medline CASGoogle Scholar
• 11 Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7(8), 656–664 (2010).
  Medline CASGoogle Scholar
• 12 Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82(4), 239–259 (1991).
  Medline CASGoogle Scholar
• 13 Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18(4), 351–357 (1997).
  Medline CASGoogle Scholar
• 14 Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70(11), 960–969 (2011).
  Medline CASGoogle Scholar
• 15 Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J et al. Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am. J. Pathol. 157(2), 623–636 (2000).
  Medline CASGoogle Scholar
• 16 Ahmed RM, Paterson RW, Warren JD et al. Biomarkers in dementia: clinical utility and new directions. J. Neurol. Neurosurg. Psychiatry 85(12), 1426–1434 (2014).
  Medline CASGoogle Scholar
• 17 Grundke-Iqbal I, Iqbal K, Tung YC et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83(13), 4913–4917 (1986). •• This study described the discovery of the abnormal hyperphosphorylation of tau in neurofibrillary tangles in AD.
  Medline CASGoogle Scholar
• 18 Wischik CM, Novak M, Thøgersen HC et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc. Natl Acad. Sci. USA 85(12), 4506–4510 (1988).
  Medline CASGoogle Scholar
• 19 Wischik CM, Novak M, Edwards PC et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85(13), 4884–4888 (1988).
  Medline CASGoogle Scholar
• 20 Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 26(7), 1015–1022 (2005).
  Medline CASGoogle Scholar
• 21 Yan SD, Chen X, Schmidt AM et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl Acad. Sci. USA 91(16), 7787–7791 (1994).
  Medline CASGoogle Scholar
• 22 Reynolds MR, Berry RW, Binder LI. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry 44(5), 1690–1700 (2005).
  Medline CASGoogle Scholar
• 23 Min SW, Cho SH, Zhou Y et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6), 953–966 (2010).
  Medline CASGoogle Scholar
• 24 Liu F, Iqbal K, Grundke-Iqbal I et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl Acad. Sci. USA 101(29), 10804–10809 (2004). •• This study reported the discovery of global decrease in O-GlcNAcylation and the regulation of phosphorylation of tau by this post-translational modification in AD brain.
  Medline CASGoogle Scholar
• 25 Perry G, Mulvihill P, Fried VA et al. Immunochemical properties of ubiquitin conjugates in the paired helical filaments of Alzheimer disease. J. Neurochem. 52(5), 1523–1528 (1989).
  Medline CASGoogle Scholar
• 26 Kolarova M, García-Sierra F, Bartos A et al. Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers Dis. 2012, 731526 (2012).
  MedlineGoogle Scholar
• 27 Kimura T, Fukuda T, Sahara N et al. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285(49), 38692–38699 (2010).
  Medline CASGoogle Scholar
• 28 Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 103(23), 8864–8869 (2006).
  MedlineGoogle Scholar
• 29 Iqbal K, Alonso Adel C, Grundke-Iqbal I. Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J. Alzheimers Dis. 14(4), 365–370 (2008).
  MedlineGoogle Scholar
• 30 Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443(7113), 780–786 (2006).
  Medline CASGoogle Scholar
• 31 Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284(19), 12845–12852 (2012).
  Google Scholar
• 32 Clavaguera F, Bolmont T, Crowther RA et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell. Biol. 11(7), 909–913 (2009).
  Medline CASGoogle Scholar
• 33 de Calignon A, Polydoro M, Suárez-Calvet M et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4), 685–697 (2012).
  Medline CASGoogle Scholar
• 34 Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27(34), 9115–9129 (2007). •• This study described the first successful reduction of tau pathology in JNPL3 (P301L) mice immunized with a tau phosphopeptide.
  Medline CASGoogle Scholar
• 35 Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6), 857–868 (2005).
  Medline CASGoogle Scholar
• 36 Iqbal K, Liu F, Gong CX et al. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118(1), 53–69 (2009).
  Medline CASGoogle Scholar
• 37 de Calignon A, Spires-Jones TL, Pitstick R et al. Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68(7), 757–761 (2009).
  Medline CASGoogle Scholar
• 38 Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316(5825), 750–754 (2007).
  Medline CASGoogle Scholar
• 39 Vossel KA, Zhang K, Brodbeck J et al. Tau reduction prevents A{beta}-induced defects in axonal transport. Science 330(6001), 198 (2010).
  Medline CASGoogle Scholar
• 40 Rhein V, Song X, Wiesner A et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl Acad. Sci. USA 106(47), 20057–20062 (2009).
  Medline CASGoogle Scholar
• 41 Vershinin M, Carter BC, Razafsky DS et al. Multiple-motor based transport and its regulation by tau. Proc. Natl Acad. Sci. USA 104(1), 87–92 (2007).
  Medline CASGoogle Scholar
• 42 Ittner LM, Fath T, Ke YD et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl Acad. Sci. USA 105(41), 15997–16002 (2008).
  Medline CASGoogle Scholar
• 43 Ittner LM, Ke YD, Gotz J. Phosphorylated tau interacts with c-Jun N-terminal kinase interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 284(31), 20909–20916 (2009).
  Medline CASGoogle Scholar
• 44 Eckert A, Schulz KL, Rhein V, Götz J. Convergence of Amyloid-beta and tau pathologies on mitochondria in vivo. Mol. Neurobiol. 41(-3), 107–114 (2010).
  Medline CASGoogle Scholar
• 45 Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1), 631–639 (1992).
  Medline CASGoogle Scholar
• 46 Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 24(10), 1355–1360 (2015). • A comprehensive review of current drug therapies aimed at targeting the tau protein.
  Medline CASGoogle Scholar
• 47 Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59(2), 750–753 (1992). •• This study for the first time described that the brain level of tau is approximately four- to five-fold increased in AD and that this increase is in the form of abnormally hyperphosphorylated tau.
  Medline CASGoogle Scholar
• 48 Wen Y, Planel E, Herman M et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28(10), 2624–2632 (2008).
  Medline CASGoogle Scholar
• 49 Tolosa E, Litvan I, Höglinger GU et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29(4), 470–478 (2014). • The negative Tau Restoration on PSP (TAUROS) Phase II trial on the glycogen synthase kinase-3 (GSK-3) inhibitor tideglusib for the treatment of progressive supranuclear palsy (PSP).
  Medline CASGoogle Scholar
• 50 Del Ser T, Steinwachs KC, Gertz HJ et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J. Alzheimers Dis. 33(1), 205–215 (2013).
  Medline CASGoogle Scholar
• 51 Lovestone S, Boada M, Dubois B et al. ARGO investigators. A Phase II trial of tideglusib in Alzheimer's disease. J. Alzheimers Dis. 45(1), 75–88 (2015).
  Medline CASGoogle Scholar
• 52 Kins S, Crameri A, Evans DR et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem. 276(41), 38193–38200 (2001).
  Medline CASGoogle Scholar
• 53 Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease. Future Med. Chem. 3(7), 821–833 (2011).
  Medline CASGoogle Scholar
• 54 Medina M, Avila J. Further understanding of tau phosphorylation: implications for therapy. Expert Rev. Neurother. 15(1), 115–122 (2015).
  Medline CASGoogle Scholar
• 55 Wang X, Blanchard J, Kohlbrenner E et al. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 24(11), 4420–4321 (2010). • These studies showed that adeno-associated virus vector-mediated expression of I2CTF or I2NTF and I2CTF replicate several features of AD including abnormal hyperphosphorylation and sarkosyl insoluble tau, and cognitive impairment in rats.
  Medline CASGoogle Scholar
• 56 Landrieu I, Smet-Nocca C, Amniai L et al. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PLoS ONE 6(6), e21521 (2011).
  Medline CASGoogle Scholar
• 57 Sontag JM, Nunbhakdi-Craig V, Sontag E. Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatases 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells. J. Biol. Chem. 288(38), 27396–27405 (2013).
  Medline CASGoogle Scholar
• 58 Grundke-Iqbal I, Iqbal K, Quinlan M et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261(13), 6084–6089 (1986).
  Medline CASGoogle Scholar
• 59 Iqbal K, Grundke-Iqbal I, Zaidi T et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 2(8504), 421–426 (1986). • This study described the discovery of the cytosolic abnormally hyperphosphorylated tau in AD and inhibition of in vitro microtubule assembly by it.
  Medline CASGoogle Scholar
• 60 Butler D, Bendiske J, Michaelis M et al. Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur. J. Pharmacol. 562(1–2), 20–27 (2007).
  Medline CASGoogle Scholar
• 61 Zhang B, Carroll J, Trojanowski JQ et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32(11), 3601–3611 (2012). • This study described the microtubule-stabilizing agent epothilone D in animal tau model of AD.
  Medline CASGoogle Scholar
• 62 Cortice biosciences announces results from studies evaluating pipeline candidates TPI 287 and CRT 001 in preclinical models of tauopathies and Alzheimer's disease. http://globenewswire.com/newsrelease/2014/11/12/682514/10107850/en/Cortice-Biosciences-Announces-Results-From-Studies-Evaluating-Pipeline-Candidates-TPI-287-and-CRT-001-in-Preclinical-Models-of-Tauopathies-and-Alzheimer-s-Disease.html
  Google Scholar
• 63 Bassan M, Zamostiano R, Davidson A et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72(3), 1283–1293 (1999).
  Medline CASGoogle Scholar
• 64 Vulih-Shultzman I, Pinhasov A, Mandel S et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 323(2), 438–449 (2007).
  Medline CASGoogle Scholar
• 65 Gozes I, Giladi E, Pinhasov A et al. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293(3), 1091–1098 (2000).
  Medline CASGoogle Scholar
• 66 Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Curr. Pharm. Des. 17(10), 1040–1044 (2011).
  Medline CASGoogle Scholar
• 67 Gozes I, Schirer Y, Idan-Feldman A et al. NAP alpha-aminoisobutyric acid (IsoNAP). J. Mol. Neurosci. 52(1), 1–9 (2014).
  Medline CASGoogle Scholar
• 68 Boxer AL, Lang AE, Grossman M et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 13, 676–685 (2014). • The substantially negative Phase II trial of davunetide, a compound able to promote microtubule stability and reduce tau phosphorylation, in patients with PSP.
  Medline CASGoogle Scholar
• 69 Cisek K, Cooper GL, Huseby CJ, Kuret J. Structure and mechanism of action of tau aggregation inhibitors. Curr. Alzheimer Res. 11(10), 918–927 (2014). • A comprehensive and very updated review of the structures and mechanisms of principal covalent and noncovalent TAIs.
  Medline CASGoogle Scholar
• 70 Taniguchi S, Suzuki N, Masuda M et al. Inhibition of heparin-induced Tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280(9), 7614–7623 (2005).
  Medline CASGoogle Scholar
• 71 Wischik CM, Edwards PC, Lai RY et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA 93(20), 11213–11218 (1996). •• First study in which phenothiazines were proposed as TAIs for AD treatment.
  Medline CASGoogle Scholar
• 72 Crowe A, James MJ, Lee VM et al. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J. Biol. Chem. 288(16), 11024–11037 (2013).
  Medline CASGoogle Scholar
• 73 Schafer KN, Cisek K, Huseby CJ et al. Structural determinants of Tau aggregation inhibitor potency. J. Biol. Chem. 288(45), 32599–32611 (2013).
  Medline CASGoogle Scholar
• 74 Kees F. Dimethyl fumarate: a Janus-faced substance? Expert Opin. Pharmacother. 14(11), 1559–1567 (2013).
  Medline CASGoogle Scholar
• 75 Wischik CM, Staff RT, Wischik DJ et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J. Alzheimers Dis. 44(2), 705–720 (2015). •• Completed Phase II study regarding derivative of methylthioninium (MT).
  Medline CASGoogle Scholar
• 76 Harrington CR, Storey JM, Clunas S et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J. Biol. Chem. 290(17), 10862–10875 (2015). •• This paper described primary synthesis and characterization of TRx0237, the critical concentration required for dissolution of tau aggregates isolated from AD brain tissues and two cellular models developed to measure the prion-like processing of tau protein in living cell systems and measurement of tau aggregation inhibition activity of novel drug candidates.
  Medline CASGoogle Scholar
• 77 Melis V, Magbagbeolu M, Rickard JE et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav. Pharmacol. 26(4), 353–368 (2015). •• An analysis of results from the use of MT and TRx0237 in two transgenic models and defining the brain concentration range for tau aggregation inhibition activity for MT in vivo.
  Medline CASGoogle Scholar
• 78 Baddeley TC, McCaffrey J, Storey JM et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J. Pharmacol. Exp. Ther. 352(1), 110–118 (2015). •• This article presented the four Phase I studies and two preclinical studies that were required to get to the bottom of the bioavailability limitations of the form of MT tested in the Phase II trial and represented the basis for proceeding into Phase III with TRx0237.
  MedlineGoogle Scholar
• 79 Wisniewski T, Drummond E. Developing therapeutic vaccines against Alzheimer's disease. Expert Rev. Vaccines 15(3) 401–415 (2016).
  Medline CASGoogle Scholar
• 80 Götz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br. J. Pharmacol. 165(5), 1246–1259 (2012).
  Medline CASGoogle Scholar
• 81 Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 288(49), 35452–35465 (2013).
  Medline CASGoogle Scholar
• 82 Gu J, Congdon EE, Sigurdsson EM. Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau pathology. J. Biol. Chem. 288(46), 33081–33095 (2013).
  Medline CASGoogle Scholar
• 83 Collin L, Bohrmann B, Göpfert U, Oroszlan-Szovik K, Ozmen L, Grüninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 137(Pt 10), 2834–2846 (2014).
  MedlineGoogle Scholar
• 84 Congdon EE, Krishnaswamy S, Sigurdsson EM. Harnessing the immune system for treatment and detection of tau pathology. J. Alzheimers Dis. 40(Suppl. 1), S113–S121 (2014).
  MedlineGoogle Scholar
• 85 Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem. 113(5), 1188–1199 (2010).
  Medline CASGoogle Scholar
• 86 Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6), 857–868 (2005).
  Medline CASGoogle Scholar
• 87 Tampellini D, Magrane J, Takahashi RH et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem. 282(26), 18895–18906 (2007).
  Medline CASGoogle Scholar
• 88 Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 293(5534), 1491–1495 (2001).
  Medline CASGoogle Scholar
• 89 Lewis J, Dickson DW, Lin W-L et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293(5534), 1487–1491 (2001).
  Medline CASGoogle Scholar
• 90 Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3), 321–332 (2004).
  Medline CASGoogle Scholar
• 91 Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287(23), 19440–19451 (2012).
  Medline CASGoogle Scholar
• 92 Yanamandra K, Kfoury N, Jiang H et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80(2), 402–414 (2013).
  Medline CASGoogle Scholar
• 93 Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118(4), 658–667 (2011). •• First study in which a passive immunization antitau protein was studied in an animal model with decreased tau pathology and functional impairments.
  Medline CASGoogle Scholar
• 94 Rosenmann H, Grigoriadis N, Karussis D et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63(10), 1459–1467 (2006).
  MedlineGoogle Scholar
• 95 Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30(49), 16559–16566 (2010).
  Medline CASGoogle Scholar
• 96 Kontsekova E, Zilka N, Kovacech B et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res. Ther. 6(4), 44 (2014). •• First tau vaccine for AD.
  MedlineGoogle Scholar
• 97 Paholikova K, Salingova B, Opattova A et al. N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J. Alzheimers Dis. 43(3), 915–926 (2015).
  Medline CASGoogle Scholar
• 98 Encouraging Results of AXON's Tau Vaccine Advance Alzheimer's Therapy - Washington, D.C., July 23, 2015. www.axon-neuroscience.eu/docs/press-release-axon-post-aaic.pdf
  Google Scholar
• 99 Theunis C, Crespo-Biel N, Gafner V et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS ONE 8(8), e72301 (2013).
  MedlineGoogle Scholar
• 100 Chai X, Wu S, Murray TK et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J. Biol. Chem. 286(39), 34457–34467 (2011).
  Medline CASGoogle Scholar
• 101 Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 288(49), 35452–35465 (2013).
  Medline CASGoogle Scholar
• 102 Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J. Biol. Chem. 288(46), 33081–33095 (2013).
  Medline CASGoogle Scholar
• 103 Kontsekova E, Ivanovova N, Handzusova M, Novak M. Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell. Mol. Neurobiol. 29(6–7), 793–788 (2009).
  Medline CASGoogle Scholar
• 104 Taniguchi T, Sumida M, Hiraoka S et al. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett. 579(6), 1399–1404 (2005).
  Medline CASGoogle Scholar
• 105 Zilka N, Kontsekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J. Alzheimers Dis. 15, 169–179 (2008).
  Medline CASGoogle Scholar
• 106 Kontsekova E, Zilka N, Kovacech B et al. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res. Ther. 6(4), 45 (2014).
  MedlineGoogle Scholar
• 107 Buée L, Bussière T, Buée-Scherrer V et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33(1), 95–130 (2000).
  Medline CASGoogle Scholar
• 108 Collin L, Bohrmann B, Göpfert U et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 137(Pt 10), 2834–2846 (2014). • Monoclonal antibody for treatment of tau in a mouse model of AD.
  MedlineGoogle Scholar
• 109 Troquier L, Caillierez M, Burnouf S et al. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 9(4), 397–405 (2012).
  MedlineGoogle Scholar
• 110 Bae EJ, Lee HJ, Rockenstein E et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32(39), 13454–13469 (2012).
  Medline CASGoogle Scholar
• 111 F. Hoffmann-La Roche Ltd. Product Development Portfolio. Pharma pipeline changes. www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
  Google Scholar
• 112 Bright J, Hussain S, Dang V et al. Human secreted tau increases amyloid-beta production. Neurobiol. Aging 36(2), 693–709 (2015).
  Medline CASGoogle Scholar
• 113 Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. Acta Neuropathol. 121(5), 589–595 (2011).
  Medline CASGoogle Scholar
• 114 Yanamandra K, Kfoury N, Jiang H et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80(2), 402–414 (2013).
  Medline CASGoogle Scholar
• 115 Yanamandra K, Jiang H, Mahan TE et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2(3), 278–288 (2015).
  Medline CASGoogle Scholar
• 116 Dai CL, Chen X, Kazim SF et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J. Neural. Transm. (Vienna) 122(4), 607–617 (2015).
  Medline CASGoogle Scholar
• 117 Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25(1), 59–68 (2007). • This study demonstrated that protein phosphatase-2A regulated the abnormal phosphorylation sites of tau and that catalysis by more than one combination of tau protein kinases could lead to the abnormal hyperphosphorylation of tau.
  MedlineGoogle Scholar
• 118 Ragupathi G, Gathuru J, Livingston P. Antibody inducing polyvalent cancer vaccines. Cancer Treat. Res. 123, 157–180 (2005).
  Medline CASGoogle Scholar
• 119 Willet M, Kurup D, Papaneri A et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J. Infect. Dis. 212(Suppl. 2), S414–S424 (2015).
  Medline CASGoogle Scholar
• 120 Morris M, Knudsen GM, Maeda S et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18(8), 1183–1189 (2015).
  Medline CASGoogle Scholar
• 121 Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85(1), 115–122 (2013).
  Google Scholar
• 122 Han DH, Na HK, Choi WH et al. Direct cellular delivery of human proteasomes to delay tau aggregation. Nat. Commun. 5, 5633, (2014).
  Medline CASGoogle Scholar
• 123 Myeku N, Clelland CL, Emrani S et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat. Med. 22(1), 46–53 (2016).
  Medline CASGoogle Scholar
• 124 Min SW, Chen X, Tracy TE et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21(10), 1154–1162 (2015).
  Medline CASGoogle Scholar
• 125 Cook C, Carlomagno Y, Gendron TF et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23(1), 104–116 (2014).
  Medline CASGoogle Scholar
• 126 Wang JZ, Zhang Y. Configuration-specific immunotherapy targeting cis pThr231-Pro232 tau for Alzheimer disease. J. Neurol. Sci. 348(1–2), 253–255 (2015).
  Medline CASGoogle Scholar
• 127 Sigurdsson EM. Tau immunotherapy and imaging. Neurodegener. Dis. 13(2), 103–106 (2014).
  Medline CASGoogle Scholar
• 128 Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34(12), 4260–4272 (2014).
  MedlineGoogle Scholar